Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)

Trial Profile

Open Label Study to Assess the Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Children and Adolescents (3 to <18 years) with Developmental and Epileptic Encephalopathy (BELIEVE 1)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BELIEVE 1
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2018 Status changed from recruiting to active, no longer recruiting, according to a Zynerba Pharmaceuticals media release.
    • 17 Dec 2018 According to a Zynerba Pharmaceuticals media release, the company expects to report top-line results from this trial in the third quarter of 2019.
    • 08 Nov 2018 According to a Zynerba Pharmaceuticals media release, the company expects to complete enrolment in this trial by the end of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top